title: Pneumococcal polysaccharide vaccine efficacy. An evaluation of current recommendations.
abstract: OBJECTIVE
  To determine pneumococcal polysaccharide vaccine efficacy in selected populations at risk for serious pneumococcal infection for whom vaccination is currently recommended and to assess duration of protection after vaccination.
  
  
  METHODS
  Vaccine efficacy was estimated using indirect cohort analysis to compare the proportion of pneumococcal infections caused by serotypes included in the vaccines of vaccinated and unvaccinated persons who were identified during 14 years of national surveillance.
  
  
  METHODS
  Hospital laboratories in the United States that submitted pneumococcal isolates to the Centers for Disease Control and Prevention between May 1978 and April 1992.
  
  
  METHODS
  A total of 2837 persons older than 5 years who had pneumococcus isolated from blood or cerebrospinal fluid.
  
  
  RESULTS
  Overall efficacy for preventing infection caused by serotypes included in the vaccine was 57% (95% confidence interval [CI], 45% to 66%). Efficacy among persons with diabetes mellitus was 84% (95% CI, 50% to 95%); with coronary vascular disease, 73% (95% CI, 23% to 90%); with congestive heart failure, 69% (95% CI, 17% to 88%); with chronic pulmonary diseases, 65% (95% CI, 26% to 83%); and with anatomic asplenia, 77% (95% CI, 14% to 95%). Efficacy was not documented for patients with alcoholism or cirrhosis, sickle cell disease, chronic renal failure, lymphoma, leukemia, or multiple myeloma, although sample sizes were small for these groups. Efficacy for immunocompetent persons older than 65 years was 75% (95% CI, 57% to 85%). Efficacy did not decline with increasing interval after vaccination: 5 to 8 years after vaccination it was 71% (95% CI, 24% to 89%), and 9 years or more after vaccination it was 80% (95% CI, 16% to 95%).
  
  
  CONCLUSIONS
  Intensified efforts to improve pneumococcal vaccine coverage among certain populations for whom vaccination is currently recommended is indicated, but universal revaccination is not warranted at this time.
authors.affiliation: Respiratory Diseases Branch, Division of Bacterial and Mycotic Diseases, Centers for Disease Control and Prevention, Atlanta, GA 30333.
authors.forename: J C
authors.initials: JC
authors.lastname: Butler
authors.forename: R F
authors.initials: RF
authors.lastname: Breiman
authors.forename: J F
authors.initials: JF
authors.lastname: Campbell
authors.forename: H B
authors.initials: HB
authors.lastname: Lipman
authors.forename: C V
authors.initials: CV
authors.lastname: Broome
authors.forename: R R
authors.initials: RR
authors.lastname: Facklam
mesh_terms: D000293:Adolescent; D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D001428:Bacterial Vaccines / Q000592:standards; D002648:Child; D002675:Child, Preschool; D015331:Cohort Studies; D004341:Drug Evaluation; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D011008:Pneumococcal Infections / Q000453:epidemiology / Q000382:microbiology / Q000517:prevention & control*; D022242:Pneumococcal Vaccines; D011159:Population Surveillance; D012307:Risk Factors; D012703:Serotyping; D013296:Streptococcus pneumoniae / Q000145:classification*; D014481:United States / Q000453:epidemiology; D014611:Vaccination / Q000592:standards
chemical_list: D001428:Bacterial Vaccines; D022242:Pneumococcal Vaccines